Medivir—focusing on cancer one prodrug at a time

Medivir is developing tumor-directed nucleotide oral prodrugs to treat cancers with highly unmet medical needs. The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug that Medivir is looking to develop alone in the USA and the EU and through partnerships elsewhere.

Like 0 Comment
Page of
Go to the profile of Medivir


COO, Medivir

Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer. To do this efficiently and with a high success rate, we bring together a unique combination of clinical development skills, a collaborative culture and an extensive industry experience, with a balanced project portfolio.

No comments yet.